Paul Elvin

Title: Paul Elvin: Innovator in Targeted Binding Agents

Introduction

Paul Elvin is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of biotechnology, particularly in the development of targeted binding agents. With a total of 2 patents, his work focuses on innovative solutions for medical diagnostics and therapeutics.

Latest Patents

Elvin's latest patents include "Targeted binding agents directed to uPAR and uses thereof." This patent describes fully human monoclonal antibodies directed to the antigen uPAR. It encompasses nucleotide sequences encoding heavy and light chain immunoglobulin molecules, particularly those corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs). His second patent, titled "Assay method," provides a method for measuring the activity of plasminogen activators, such as urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA) in biological samples. This method is characterized by the inclusion of an elastase inhibitor in the assay mixture, and it also offers a diagnostic kit for measuring plasminogen activators.

Career Highlights

Throughout his career, Paul Elvin has worked with prominent companies in the biotechnology sector, including MedImmune Limited and AstraZeneca AB. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.

Collaborations

Elvin has collaborated with notable colleagues, including Qing Zhou and Stephen Charles Emery. These partnerships have further enhanced his research and development efforts in the field.

Conclusion

Paul Elvin's contributions to the field of biotechnology through his patents and collaborations highlight his role as an innovator. His work continues to impact medical diagnostics and therapeutics, showcasing the importance of targeted binding agents in modern medicine.